332 related articles for article (PubMed ID: 30652574)
1. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.
Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C
JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J; Chen EY; Prasad V
JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
[TBL] [Abstract][Full Text] [Related]
3. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
5. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
Bruinooge SS; Sherwood S; Grubbs S; Schilsky RL
J Oncol Pract; 2019 Nov; 15(11):575-583. PubMed ID: 31386607
[TBL] [Abstract][Full Text] [Related]
6. Database of evidence for precision oncology portal.
Sun SQ; Mashl RJ; Sengupta S; Scott AD; Wang W; Batra P; Wang LB; Wyczalkowski MA; Ding L
Bioinformatics; 2018 Dec; 34(24):4315-4317. PubMed ID: 30535306
[TBL] [Abstract][Full Text] [Related]
7. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
8. Evidence-Based Network Approach to Recommending Targeted Cancer Therapies.
Kancherla J; Rao S; Bhuvaneshwar K; Riggins RB; Beckman RA; Madhavan S; Corrada Bravo H; Boca SM
JCO Clin Cancer Inform; 2020 Jan; 4():71-88. PubMed ID: 31990579
[TBL] [Abstract][Full Text] [Related]
9. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
10. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
11. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
[TBL] [Abstract][Full Text] [Related]
13. Open Targets Platform: supporting systematic drug-target identification and prioritisation.
Ochoa D; Hercules A; Carmona M; Suveges D; Gonzalez-Uriarte A; Malangone C; Miranda A; Fumis L; Carvalho-Silva D; Spitzer M; Baker J; Ferrer J; Raies A; Razuvayevskaya O; Faulconbridge A; Petsalaki E; Mutowo P; Machlitt-Northen S; Peat G; McAuley E; Ong CK; Mountjoy E; Ghoussaini M; Pierleoni A; Papa E; Pignatelli M; Koscielny G; Karim M; Schwartzentruber J; Hulcoop DG; Dunham I; McDonagh EM
Nucleic Acids Res; 2021 Jan; 49(D1):D1302-D1310. PubMed ID: 33196847
[TBL] [Abstract][Full Text] [Related]
14. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
15. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
16. BIOMedical Search Engine Framework: Lightweight and customized implementation of domain-specific biomedical search engines.
Jácome AG; Fdez-Riverola F; Lourenço A
Comput Methods Programs Biomed; 2016 Jul; 131():63-77. PubMed ID: 27265049
[TBL] [Abstract][Full Text] [Related]
17. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
[TBL] [Abstract][Full Text] [Related]
18. IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics.
Hintzsche JD; Yoo M; Kim J; Amato CM; Robinson WA; Tan AC
BMC Med Genomics; 2018 Apr; 11(Suppl 2):26. PubMed ID: 29697364
[TBL] [Abstract][Full Text] [Related]
19. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
20. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
